FILE PHOTO: A vial and syringe are seen in front of a displayed Pfizer logo in this illustration taken Jan 11, 2021. BRUSSELS: The European Union cemented its support for Pfizer-BioNTech and its novel COVID-19 vaccine technology on Saturday by agreeing to a massive contract extension for a potential 1.8 billion doses through 2023.
The European Commission currently has a portfolio of 2.6 billion doses from half a dozen companies. “Other contracts and other vaccine technologies will follow,” von der Leyen said in a Twitter message.Advertisement The active ingredient in the Pfizer-BioNTech shot is messenger RNA, or mRNA, which contains the instructions for human cells to construct a harmless piece of the coronavirus called the spike protein. The human immune system recognises the spike protein as foreign, allowing it to mount a response against the virus upon infection.
In contrast to the oft-criticised Anglo-Swedish AstraZeneca, von der Leyen has said that Pfizer-BioNTech is a reliable partner that delivers on its commitments.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.